Advertisement

Alberta’s health minister signs onto federal deal for rare disease medications

Click to play video: 'Alberta to receive $162 million on rare disease drug agreement'
Alberta to receive $162 million on rare disease drug agreement
The provincial government has signed a multi-million dollar agreement with the federal government to give access to drugs for rare diseases. The pair has also created a list of rare disease drugs to help inform future approvals. Kabi Moulitharan reports. – Dec 5, 2024

Alberta Health Minister Adriana LaGrange has signed a deal with her federal counterpart to expand access to medication for people with rare diseases.

LaGrange joined federal Health Minister Mark Holland in Edmonton to announce millions in spending on both emerging and proven drugs, as well as on diagnostics and screening.

The drugs include Poteligeo for treating Sézary syndrome, Oxlumo for hyperoxaluria type 1 and Epkinly for large B-cell lymphoma.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

LaGrange says the move will help support Albertans living with rare diseases and open the door to potentially life-changing treatments.

Holland says the deal is a step toward building a stronger public health system for Albertans and aims to give Albertans with rare diseases the “best health outcomes possible.”

Alberta is the third province behind B.C. and Newfoundland and Labrador to sign onto a federal deal under the National Strategy for Drugs for Rare Diseases.

Story continues below advertisement

Sponsored content

AdChoices